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Abstract
Paclitaxel is a powerful chemotherapeutic drug, used for the treatment of many cancer types,
including esophageal adenocarcinomas (EAC). Autophagy is a lysosome-dependent degrada-
tion process maintaining cellular homeostasis. Defective autophagy has been implicated in
cancer biology and therapy resistance. We aimed to assess the impact of autophagy on che-
motherapy response in EAC, with a special focus on paclitaxel. Responsiveness of EAC cell
lines, OE19, FLO-1, OE33 and SK-GT-4, to paclitaxel was assessed using Alamar Blue
assays. Autophagic flux upon paclitaxel treatment in vitro was assessed by immunoblotting of
LC3B-II and quantitative assessment of WIP1 mRNA. Immunohistochemistry for the autop-
hagy markers LC3B and p62 was applied on tumor tissue from 149 EAC patients treated with
neoadjuvant chemotherapy, including pre- and post-therapeutic samples (62 matched pairs).
Tumor response was assessed by histology. For comparison, previously published data on
114 primary resected EAC cases were used. EAC cell lines displayed differing responsiveness
to paclitaxel treatment; however this was not associated with differential autophagy regulation.
High p62 cytoplasmic expression on its own (p 0.001), or in combination with low LC3B (p =
0.034), was associated with nonresponse to chemotherapy, regardless of whether or not the
regiments contained paclitaxel, but there was no independent prognostic value of LC3B or p62
expression patterns for EAC after neoadjuvant treatment. p62 and related pathways, most
likely other than autophagy, play a role in chemotherapeutic response in EAC in a clinical set-
ting. Therefore p62 could be a novel therapeutic target to overcome chemoresistance in EAC.
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Introduction
Paclitaxel (Taxol) is a member of the taxane family, which are powerful chemotherapeutic
drugs, preventing cell division by disruption of microtubule function. It is widely used for the
treatment of a variety of cancers, including breast, ovarian, lung and gastrointestinal carcino-
mas. Esophageal Adenocarcinomas (EAC) are highly malignant tumors that often are already
locally and systemically advanced at the time of diagnosis [1]. Improved surgery and multi-
modal therapeutic concepts, including neoadjuvant chemotherapy or radiochemotherapy
have improved the prognosis of EAC patients, however, the considerable high rate of resis-
tance to conventional chemotherapy is still a major problem for the treatment of this cancer
[2]. In this context, biomarkers for the prediction of response to chemotherapy could help for
a proper patient selection, both for neoadjuvant and adjuvant or palliative therapy avoiding
side-effects of unnecessary treatment. In addition, there is a need for therapeutic strategies
aimed at overcoming chemotherapy resistance. Such approaches may encompass interference
with deregulated cellular mechanisms or pathways, or targeting molecular events that are
responsible for primary or acquired therapy resistance.
Macro-autophagy, in the following shortly referred to as “autophagy” is a highly regulated
and conserved cellular catabolic progress that degrades and recycles cellular components such
as organelles and proteins. Under basal conditions autophagy is contributing to the mainte-
nance of cellular homeostasis. Under cellular stress, such as starvation, autophagy is a survival
mechanism, as products of degradation can be recycled and reused for essential cellular pro-
cesses [3]. Dysregulation of autophagy has been described in many diseases including infec-
tions, neurodegenerative diseases or heart diseases [4–6]. In cancer, autophagy has been
suggested to play a dual role as it can act both pro- and anti-oncogenic. In early stages of malig-
nant diseases, autophagy may have a tumor suppressor function because it can degrade harmful
proteins and maintains genomic stability. In contrast, in later stages of malignant progression,
autophagy can be used by the cancer cells as a survival mechanism that facilitates invasion,
metastasis and prevents treatment induced cell death [7].
Several reports point to the potential role of autophagy for therapy resistance in EAC, mostly
based on results of in vitro experiments. We have reported on the role of the autophagy markers
LC3B and p62 in primary resected EAC in a treatment chemo-naïve setting showing that low
LC3B and low p62 expression is associated with worse outcome in, chemo-naïve carcinomas.
In this study we investigated tissue samples from patients with EAC that had been treated
with neoadjuvant chemotherapy before surgery, and performed additional in vitro experi-
ments aiming at a) elucidating the role of autophagy for later therapy response b) investigate
whether an induction of autophagy can be observed during treatment and c) whether different
expression patterns of LC3B and p62, as well as p62 related markers Kelch-like ECH-associ-
ated protein 1 (KEAP1), nuclear factor erythroid 2 (NFE2)-related factor 2 (NRF2) and nuclear
factor kappa B (NF-κB), indicating distinct forms of autophagy activation are associated with
therapy response or resistance, with a particular focus on paclitaxel treatment.
Materials and methods
Cell lines, culture and treatment conditions
The human EAC cancer cell lines OE19, OE33, SK-GT-4 and FLO-1 from the Public Health
England Culture Collections were obtained via Sigma-Aldrich, Buchs, Switzerland. OE19,
OE33 and SK-GT-4 were cultured and maintained in RPMI-1640 (Sigma-Aldrich, Buchs,
Switzerland, R8758) supplemented with 10% fetal bovine serum (Sigma-Aldrich, Buchs, Swit-
zerland, F7524) and 1% penicillin streptomycin (Sigma-Aldrich, Buchs, Switzerland, P4333).
LC3B and p62 and chemotherapy response in esophageal adenocarcinomas
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FLO-1 were cultured and maintained in DMEM (Sigma-Aldrich, Buchs, Switzerland, D5796)
supplemented with 10% FBS and 1% penicillin streptomycin. All cell lines were cultured in a
humidified incubator containing 5% CO2 at 37˚C.
Powdered paclitaxel (Sigma-Aldrich, Buchs, Switzerland, T7191) was reconstituted in
dimethyl sulfoxide (DMSO) and stock solutions were stored at -80˚C. Paclitaxel was diluted to
the final concentrations indicated in the text in complete medium. Powdered Bafilomycin A1
(Enzo-Life Sciences, Lausen, Switzerland, BML-CM110) was reconstituted in DMSO and
stock solutions stored at -20˚C. BafA prevents autophagosome-lysosome fusion and subse-
quent degradation thereby inihibiting autophagy at late stages. If autophagic flux marker
LC3B-II shows increased levels with the treatment of interest and BafA as compared to BafA
alone this is an indication that the treatment induces autophagic flux. Autophagosomal lipi-
dated LC3B-II migrates faster than the cytosolic unlipidated LC3B-I on an SDS-PAGE gel and
therefore the two isoforms can be separated and visualized using immunoblotting. For West-
ern blot experiments BafA was added for the last two hours of paclitaxel treatment at a final
concentration of 200 nM. As a positive control for autophagy induction cells were starved by
incubation with EBSS media (Sigma-Aldrich, Buchs, Switzerland, E2888) for 6hr.
Expression plasmids, transient transfection and fluorescence microscopy
Two GFP-tagged p62 expression plasmids, GFP-p62 K7A/D69A (cytoplasmic localization) and
GFP-p62 Δ303–320 K7A/D69A (nuclear localization) were kindly provided by Terje Johansen[8].
Lentiviral vectors expressing shRNA targeting p62 and a puromycin resistance gene were pur-
chased from Sigma-Aldrich (Buchs, Switzerland, TRCN0000007234, TRCN0000007235). OE19
cells were transduced and then selected in 1.5 µg/mL puromycin as described[9]. OE19 p62
knockdown cells were plated in 6-well plates and transfected with 6 µg of p62 plasmid using Lipo-
fectamineTM 2000 (Invitrogen, Basel, Switzerland; # 11668019). Cellular localization of the two
p62 proteins was assessed using GFP fluorescence. Briefly, OE19 cells were fixed with 4% parafor-
maldehyde and mounted in fluorescence mounting medium (SlowFadeTM Gold Antifade
Mountant with DAPI, Invitrogen, Basel, Switzerland; S36938). Images were taken on an Olympus
FluoView-1000 (Olympus, Volketswil, Switzerland) confocal microscope at x60 magnification.
Alamar Blue1 assay
Relative cell viability upon paclitaxel treatment was assessed using the alamarBlue1 Assay
(ThermoFisher Scientific, Reinach, Switzerland, DAL1100) according to the manufacturer’s
instructions. The alamarBlue1 reagent consists of a redox indicator, containing the dye resa-
zurin, appearing blue in its oxidized form and red, as resazurin converted into in resorufin, in
its reduced form. Metabolically active cells are cable of catalyzing this reduction resulting in
colorimetric change which can be spectrophotometrically measured via absorbance. Cells were
plated in 96 well flat bottom plates and allowed to adhere overnight. Cells were treated with
paclitaxel and incubated with the alamarBlue for 2hr prior to the reading absorbance at 570nm
and 600nm for each indicated time point. Reduction of the alamarBlue1 reagent was calcu-
lated and represented as relative cell viability.
Western blotting
Prior to lysis with urea buffer (8 M urea, 0.5% tritonX) containing protease inhibitor (complete
midi, Roche Diagnostics, Rotkreuz, Switzerland) cells were washed in phosphate buffered
saline (PBS). Samples were sonicated, centrifuged at 13 000 rcf for 30 minutes (min) and the
resulting supernatant was transferred to a fresh tube. The Bradford protein assay (BioRad,
Cressier, Switzerland) was used to determine protein concentration, 30μg of total protein per
LC3B and p62 and chemotherapy response in esophageal adenocarcinomas
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sample was denatured in selfmade 5X sample buffer with β-mercaptoethanol (Sigma Aldrich,
M-7522) at 95˚C for 5 min and loaded on a 4–20% stain-free pre-cast gel (BioRad). Total pro-
tein was visualized as loading control using the ChemiDoc™ MP system (BioRad). Proteins
were transferred onto a polyvinylidene difluoride membrane using the Trans-Blot1 Turbo™
Transfer system (BioRad) and blocked in 5% bovine serum albumin (BSA)/TBS for 1hr at
room temperature (RT). The anti-LC3B antibody from Novus Biologicals (rabbit polyclonal,
#NB600-1384, LuBioScience, Luzern, Switzerland) was dilution 1:1000 in 5% milk/TBS with
0.1% Tween (Sigma Aldrich, P9416) and membranes were incubated overnight at 4˚C with
shaking. Goat anti-rabbit horseradish peroxidase (HRP)-linked secondary antibody (Cell Sig-
naling, Danvers MA, USA, 7076) was diluted 1:10 000 in 5% milk/TBS-T and membranes
incubated for 3hr at RT with shaking, followed by 5min incubation with the ClarityTM West-
ern ECL Substrate (BioRad, Cressier, Switzerland, 1705061) at RT with shaking. Proteins of
interest were visualized using the ChemiDoc™ MP system (BioRad, Cressier, Switzerland,
1708280). Images were adjusted for brightness and quantified using ImageJ software (1.64r;
NIH, Bethesda, MD, USA).
Quantitative real-time RT-PCR (qPCR)
The miRCURY RNA Isolation Kit from Exiqon was used for RNA extraction as per the manu-
facturer’s instructions. RT-PCR was performed as previously described [10]. The gene expres-
sion assays Hs00215872_m1 and Hs00797944_s1 (Applied Biosystems, Rotkreuz, Switzerland)
were used to quantitatively measure mRNA of WIPI1 (WD repeat domain phosphoinositide-
interacting protein 1) and LC3B, respectively. HMBS was included in analysis as a housekeep-
ing gene for normalization and primers and probes were used as previously published [11].
The ABI PRISM 7500 Sequence Detection System (Applied Biosystems, Rotkreuz, Switzer-
land) was used to perform measurements.
Flow cytometry
Cell death of GFP-p62 transfected OE19 cells was assessed using flow cytometric analysis of Alexa
Fluor1 647 (BioLegend, #640912) and DAPI. Data acquisition and analysis was carried out on a
FACS LSR-II (BD Biosciences, Switzerland) using the FlowJo software (Ashland, OR, USA).
Patients and tissue samples
Two different case collections of formalin fixed paraffin embedded (FFPE) archival pathology
tissue were used for the immunohistochemical studies. The usage of pathological archival
material for research had been approved by the local ethics commissions (Kantonale Ethik-
kommission Bern, Switzerland, 200/14 and Medizinische Fakulta¨t of the Technische Universi-
ta¨t Mu¨nchen, 2056/08). The first case collection was generated from a total of 149 patients
with locally advanced esophageal adenocarcinomas that were treated in the department of sur-
gery of the Klinikum rechts der Isar, Technische Universita¨t Mu¨nchen. Neoadjuvant treatment
consisted of a 5-FU and cisplatinum based chemotherapy with (n = 42) and without (n = 107)
paclitaxel [12]. Esophagectomy was performed in all patients as described previously [13]. Out
of this patient cohort, 127 preoperative biopsies and 83 resection specimens (including 62
matched pair samples of both biopsies and post-treatment resection specimen with residual
tumor) were available for tissue analysis. For tumor categorization, the UICC TNM classifica-
tion, 7th edition was used[14]. Tumor differentiation (grading) was assessed on pretherapeutic,
non-treated bioptic tissue. Tumor regression grading after neoadjuvant therapy was per-
formed with standardized macroscopic and histopathologic work-up as described previously
[15,16]. 12 tumors (8.1%) showed TRG1a = complete regression), 36 tumors (24.2%) TRG1b
LC3B and p62 and chemotherapy response in esophageal adenocarcinomas
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(=<10% residual tumor), 26 tumors (17.4%) TRG2 (10–50% residual tumor) and 75 tumors
(50.3%) TRG3 (=>50% residual tumors). Following previous works [17] and in line with the
results of the survival analysis that showed a survival benefit for patients with TRG1a, TRG1b
and 2 in comparison to TRG3 (for details see below), the 74 patients with TRG1a, 1b and 2
were classified as responders, and the 75 patients with TRG3 as non-responders. Table 1 sum-
marizes the clinic-pathological features of both the complete neoadjuvant treated cohort
(n = 149) and the subcohort (n = 83), for which post-treatment resection specimens were avail-
able for analysis.
For comparison, a second case collection of primary, chemo-naïve tumors from a previous
study including 114 cases was used [18]. Within this cohort, 69 cases were locally advanced
tumors (i.e. pT3-4, pN any categories according to the UICC TNM classification). This
allowed for a stage-related comparison between the locally advanced treatment naïve and
neoadjuvant treated tumors, as well as a comparison between the primary resected cases of
both case collections.
Tissue microarray
A next generation tissue microarray (ngTMA) was constructed from tumor tissue of the 83
cases where material from the post-treatment resection specimen was available. This approach
included digital annotation of scanned slides and automatic transferal of the punches was con-
structed from the FFPE tissue of the resection specimen with six randomly selected 0.6 mm
punches from each case as described previously [19]. The immunohistochemical data from the
comparison cohort were generated from a ngTMA based investigation as well [18].
Table 1. Summary of patient data for complete neoadjuvant EAC treated cohort and subcohort for which post-treatment resection specimens were available for
analysis.
Total Cohort (n = 149) Subcohort (n = 83)
Parameter Category Total % Total %
ypT category ypT0 12 8.1 0 0
ypT1 21 14.1 12 14.5
ypT2 24 16.1 16 19.3
ypT3 86 57.7 52 62.6
ypT4 6 4 3 3.6
Lymph Node Metastasis absent 57 38.3 22 26.5
present 92 61.7 61 73.5
Distant Metastasis absent 123 82.6 66 79.5
present 26 17.4 17 20.5
Grading G1-2 65 43.6 37 44.6
G3 84 56.4 46 55.4
Resection Status R0 119 79.9 62 74.7
R1 30 20.1 21 25.3
Tumor Regression Grade (TRG) 1a 12 8.1 0 0
1b 36 24.2 15 18.1
2 26 17.4 14 16.9
3 75 50.3 54 65.1
 M1 category cases had supra-regional lymph node metastases which is not considered as organ metastases.
https://doi.org/10.1371/journal.pone.0197610.t001
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Immunohistochemical staining, scoring and subclassification
The ngTMA and the biopsies were sectioned at 4 μm. Immunohistochemical staining for
LC3B and p62 was performed using an automated immunostainer (Bond RX, Leica Biosys-
tems, Heerbrugg, Switzerland) as described previously [20]: In brief, after de-paraffination,
rehydration, and antigen retrieval, the anti-LC3B antibody (Novus Biologicals #NB600-1384)
was diluted 1:4000 in tris buffer and incubated at 95˚C for 30 min. The anti-p62/SQSTM1 anti-
body (MBL rabbit polyclonal, #PM0045, LabForce, Nunningen, Switzerland) was diluted
1:9000 in tris buffer and incubated at 95˚C for 30 min. The conditions for the p62 downstream
targets and NF-κB were as follows: the anti-NRF2 (Santa Cruz #sc365949) was diluted 1:200
tris buffer and incubated at 95˚C for 30 min, the anti-KEAP1 (Proteintech #10503-2-AP) was
diluted 1:1000 tris buffer and incubated at 95˚C for 30 min and the anti- NF-κB antibody
(Abcam #ab7970) was diluted 1:1000 Citrate buffer and incubated at 95˚C for 60 min. Visuali-
zation was performed using the Bond Polymer Refine Detection kit (Leica Biosystems, Mut-
tenz, Switzerland, DS9800) according to the manufacturer’s instructions.
IHC staining patterns in tumors were scored across all cores by an experienced gastrointes-
tinal pathologist (RL), as previously described, with slight modifications according to the pres-
ent staining patterns [18, 20, 21]: LC3B and p62 dot-like immunohistochemical staining was
scored from 0 to 3 as follows: score 0—no dots visible or barely dots visible in < 5% of the
cells, score 1—detectable dots in 5–25% of the cells, score 2—detectable dots in 25–75% of the
cells, score 3—dots visible in> 75% of the cells. p62, NF-κB and KEAP1 cytoplasmic immuno-
histochemical staining was classified as score 0—no or faint cytoplasmic staining visible, score
1—weak cytoplasmic staining visible, score 2—moderate cytoplasmic staining visible and
score 3—strong cytoplasmic staining visible. p62 and NRF2 nuclear immunohistochemical
staining of tumor cells was classified as score 0—nuclear staining visible in < 10% of nuclei
and score 1—nuclear staining visible in > 10% of nuclei. For NRF2 there was an additional
score 2 for cases with>90% strong staining of nuclei. Examples of LC3B and p62
Fig 1. Examples of immunohistochemical stainings. (a) High LC3B dot like staining (score 2). (b) Low LC3B dot like staining (score 1), note a small nerve serving as
internal positive control. (c) High p62 cytoplasmic staining (score 3), while negative nuclear staining. (d) Low p62 cytoplasmic/dot-like staining (scores 0), positive
nuclear staining. (e) High cytoplasmic (score 2) and low dot-like (score 1) p62 staining. (f) Low cytoplasmic (score 1) and high dot like (score 2) p62 staining. 40x
magnification for all images. Error bars indicate 20µm.
https://doi.org/10.1371/journal.pone.0197610.g001
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immunohistochemical stainings are shown in Fig 1. Examples of NF-κB, NRF2 and KEAP1
stainings are shown in the S1 Fig. For further correlation with clinic-pathologic features the
IHC scores were categorized as either low or high for each staining pattern as described previ-
ously, with slight modifications due to the best correlative value regarding tumor regression
[18]: For LC3B and p62 dot-like and LC3B, p62, NF-κB and KEAP1 cytoplasmic staining,
scores 0 and 1 were classified as low and scores 2 and 3 were classified as high. A combination
score of p62 dot-like-cytoplasmic staining was calculated by adding dot-like and cytoplasmic
staining. Both low expression was classified as low p62 dot-like/cytoplasmic, and mixed or
both high expression was classified as high p62 dot-like/cytoplasmic staining. The dataset was
also stratified into four subtypes, which have been suggested to represent different conditions
of autophagy activation: low LC3B dot-like/low p62 dot-like-cytoplasmic staining (LL: basal
autophagy), low LC3B dot-like/high p62 dot-like-cytoplasmic staining (LH: basal autophagy,
but impaired at late stages), high LC3B dot-like/low p62 dot-like-cytoplasmic staining (HL:
intact activated autophagy) and high LC3B dot-like/high p62 dot-like-cytoplasmic staining
(HH activated autophagy, impaired at late stages) [18]. Nuclear staining for NRF2 was consid-
ered low for cores 0 and 1 and high for score 2.
Assessment of T-cell infiltrates
IHC was used for the characterization and quantification of CD8 and CD3 expressing T-cell
infiltration as previously described [22]. Briefly an automated immunostainer Bond III (Leica
Biosystems, Germany) was used and scan slides were analyzed using the Aperio ImageScope
12.2 software (Leica Biosystems). Positive cells were counted and recorded across all TMA
cores. The total cell counts of the six TMA cores was then used as the tumor infiltrating lym-
phocyte (TIL) count.
Statistical analysis
For descriptive and comparative statistical analysis the SPSS 24 software (SPSS Inc, Chicago,
IL, USA) was used. Associations between staining patterns and clinic-pathological parameters
were evaluated using cross tabs (χ-test or Fisher’s exact test). Binded samples were evaluated
using the Wilcoxon test. Survival analysis was performed using log rank test and Cox regres-
sion analysis. The significance level was set at 0.05.
Results
EAC cell lines exhibit differential response to paclitaxel treatment which is
not associated to differential autophagy regulation
The relative cell viability upon paclitaxel treatment was assessed in a panel of four EAC cell
lines using the Alamar Blue1 assay. OE19 and FLO-1 showed the least sensitivity after 24hr,
with OE33 showing a moderate response and SK-GT-4 exhibiting the highest degree of sensi-
tivity. Similar results were observed after 48hr of treatment (Fig 2). To assess whether this
observed differential drug sensitivity was associated with differential autophagy regulation or
activity Western blot analysis of autophagic flux marker LC3B-II was conducted upon treat-
ment with paclitaxel for 24hr in the absence or presence of BafA. No evidence of autophagy
induction upon paclitaxel treatment was observed in OE19, FLO-1 and SK-GT-4, as LC3B-II
levels upon paclitaxel treatment in the presence of BafA was equivalent to that of the BafA only
condition signifying no increase of autophagic flux beyond basal levels. A slight comparative
increase in LC3B-II levels were observed upon paclitaxel treatment in the presence of BafA in
OE33 suggesting autophagy induction (Fig 3A and 3B). WIPI1 and LC3B mRNA were
LC3B and p62 and chemotherapy response in esophageal adenocarcinomas
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assessed via qPCR in OE19 and OE33 upon two concentrations of paclitaxel. No evidence of
autophagy induction was observed as mRNA levels for both genes did not increase upon pacli-
taxel treatment (Fig 3C). Taken together these results indicate that the observed differential
response to paclitaxel treatment is not associated with differential autophagy regulation or
capacity to induce cytoprotective autophagy upon treatment.
High cytoplasmic p62, on its own or in combination with low LC3B, is
associated with nonresponse to chemotherapy with 5-FU/platinum and
5-FU/platinum + paclitaxel regimens in EAC
We previously published a report in which a cohort of primary resected treatment naïve EAC
patients were assessed for the autophagy markers LC3B and p62. Both single and combination
staining pattern analysis was conducted as in the present study (described in the Materials and
Methods section). Of note the primary resected treatment naïve EAC cohort was subdivided
Fig 2. EAC cell lines exhibit differential response to paclitaxel treatment. Relative cell viability upon treatment with
paclitaxel in increasing concentrations (0, 2.5, 5, 10, 20 and 40nM) was assessed using the Alamar Blue assay in OE19,
FLO-1, OE33 and SK-GT-4 after 24hr (a) and 48hr (b). Error bars indicate the standard deviation of three independent
experiments. The DMSO equivalent of the highest final concentration was added to the untreated condition as vehicle
control and relative toxicity values were normalized to the untreated controls which were set to 100%.
https://doi.org/10.1371/journal.pone.0197610.g002
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into the four categories making up the ex vivo autophagic index also utilized in this study: low
LC3B/low p62 (LL: basal autophagy), low LC3B/high p62 (LH: basal autophagy, but impaired
at late stages), high LC3B/low p62 (HL: intact activated autophagy) and high LC3B/high p62
Fig 3. Differential response to paclitaxel is not associated with differential autophagy regulation. OE19, FLO-1,
OE33 and SK-GT-4 were treated with paclitaxel, in a final concentration of 20nM, for 24hr with or without the
addition of the late stage autophagy inhibitor BafA (200nM) for the last 2hr of the 24hr paclitaxel treatment. LC3B was
visualized using Western blotting; total protein was used as loading control. (a) Representative blots of LC3B in all four
cell lines, the LC3B-I isoform is not equally visible in all cell lines at the given exposures. (b) Quantification of the
LC3B-II normalized to the total protein. Error bars indicate the standard deviation of three independent experiments.
Statistical significance was not reached when conditions where compared to one another. (c) WIP1 and LC3B mRNA
was assessed via qPCR upon treatment with paclitaxel at 20nM and 40nM for 24hr in OE19 and OE33. Nutrient
starvation, achieved with 6hr incubation with EBSS, was included in the experimental setup as a positive control for a
known autophagy inducer. Fold change was normalized to mRNA levels of housekeeping gene HBSS. The DMSO
equivalent of the highest final concentration of paclitaxel was added to the untreated condition as vehicle control and
relative values were normalized to the untreated controls which were set to 1. Error bars indicate the standard
deviation of three independent experiments.
https://doi.org/10.1371/journal.pone.0197610.g003
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(HH: activated autophagy, impaired at late stages). One of main finding in this study was that
the LL group, indicative of intact basal autophagy, faired the worse with respect to worse over-
all survival [18]. As a first aim we wanted to compare the autophagic prolife of the previously
published primary resected EAC cohort and the current neo-adjuvant chemotherapy treated
EAC cohort under investigation. Higher p62 dot-like and p62 cytoplasmic, as well as a combi-
nation of p62 dot-like and cytoplasmic expression were observed in the neo-adjuvant chemo-
therapy treated EAC cohort when compared to the treatment naïve primary resected EAC
cohort using the same criteria for the categorization into high and low expression levels. Inter-
estingly, the number of cases with high nuclear p62 in the treatment naïve primary resected
cohort superseded that of the number of cases in the neo-adjuvant chemotherapy treated EAC
cohort (Table 2). Additionally, we also assessed whether autophagic profiles between respond-
ers and non-responders significantly differed in the neo-adjuvant chemotherapy treated EAC
cohort. High p62 cytoplasmic, high p62 dot-like-cytoplasmic and low/high LC3B dot-like/p62
dot-like-cytoplasmic all significantly correlated with nonresponse in the neoadjuvant chemo-
therapy treated EAC cohort (Table 2).
In a subsequent analysis we compared the expression patterns of the autophagy markers of
entire treatment naïve EAC versus a subset of neo-adjuvant treated EAC cases treated with
5-FU/platinum + paclitaxel regimens. As with comparisons encompassing the entire neo-adju-
vant treated cohort, higher p62 dot-like and p62 cytoplasmic, as well as a combination of p62
dot-like and cytoplasmic expression (p 0.001 for all), were observed in the 5-FU/platinum
+ paclitaxel treated subset when compared to the treatment naïve primary resected EAC
cohort (Table 3).
In addition we also performed analysis comparing LC3B and p62 expression in primary
resected pT3 tumors versus pretherapeutically cT3 staged that was treated with 5-FU/platinum
and 5-FU/platinum + paclitaxel regimens. Again the results of this sub-analysis was in line
with previous results: with p62 dot-like and cytoplasmic on its own or in combination being
higher in the neo-adjuvant chemotherapy treated samples (S1 Table, p< 0.001 in all cases),
the LH LC3B/p62 category was also the most represented in the neo-adjuvant chemotherapy
subset (S2 Table, p< 0.001). Interesting higher LC3B dot-like staining was observed in the
neo-adjuvant chemotherapy subset (S2 Table, p< 0.039).
The analysis for the primary resected pT3 and pretherapeutically cT3 staged tumors was
repeated, however this time only including tumors which have received 5-FU/platinum + pacli-
taxel regimens. The results were once again in line with all previous analysis (S3 Table).
Cytoplasmic p62 renders EAC cells more resistant to paclitaxel compared
to nuclear p62
To address the question if cytoplasmic p62 contributes to paclitaxel resistance we took advan-
tage of two mutated p62 expression plasmids allowing to assess cytoplasmic and nuclear func-
tions of this protein. OE19 p62 knockdown cells were rescued with GFP-tagged cytoplasmic
and nuclear p62 expression plasmids (Fig 4A). We found that the GFP+ OE19 cell fraction
expressing the cytoplasmic p62 showed markedly decreased numbers of necrotic and late apo-
ptotic cells upon paclitaxel treatment compared to OE19 cells expressing nuclear p62. Necrotic
and late apoptotic OE19 cells decreased from 17.4% to 6.9% in nuclear compared to cyto-
plasmic p62 expressing cells (Fig 4B).
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Table 2. Comparison of expression of autophagy markers LC3B and p62 in primary resected and neo-adjuvant chemotherapy (nCTX) treated EAC cohorts. Signifi-
cance was set to 0.05. Statistically significant p-values are shown in bold.
LC3B dots Treatment Total
Primary Resected nCTX
Response Nonresponse
Low 95 21 41 157
High 19 8 13 40
Total 114 29 54 197
Treatment Naïve vs. Chemotherapy: p-value = 0.154
Response vs Nonresponse: p-value = 0.794
p62 dots Treatment Total
Primary Resected nCTX
Response Nonresponse
Low 95 18 26 139
High 19 11 28 58
Total 114 29 54 197
Treatment Naïve vs. Chemotherapy: p-value < 0.001
Response vs Nonresponse: p-value = 0.256
p62 cytoplasmic Treatment Total
Primary Resected nCTX
Response Nonresponse
Low 86 (75.4%) 21 (72.4%) 17 (31.5%) 124 (62.9%)
High 28 (24.6%) 8 (27.6%) 37 (68.5%) 73 (37.1%)
Total 114 29 54 197
Treatment Naïve vs. Chemotherapy: p-value < 0.001
Response vs Nonresponse: p-value < 0.001
p62 nuclear Treatment Total
Primary Resected nCTX
Response Nonresponse
Low 58 (50.9%) 17 (58.6%) 39 (72.2%) 114 (57.9%)
High 56 (49.1%) 12 (41.4%) 15 (27.8%) 83 (42.1%)
Total 114 29 54 197
Treatment Naïve vs. Chemotherapy: p-value = 0.028
Response vs Nonresponse: p-value = 0.228
p62 dots-cyto Treatment Total
Primary Resected nCTX
Response Nonresponse
Low 76 (66.7%) 14 (48.3%) 10 (18.5%) 100 (50.8%)
High 38 (33.3%) 15 (51.7%) 44 (81.5%) 97 (49.2%)
Total 114 29 54 197
Treatment Naïve vs. Chemotherapy: p-value = 0.006
Response vs Nonresponse: p-value < 0.001
LCB/p62 Treatment Total
Primary Resected nCTX
Response Nonresponse
LL 66 (57.9%) 11 (38.0%) 9 (16.7%) 86 (43.7%)
LH 29 (25.4%) 10 (34.5%) 32 (59.3%) 71 (36.0%)
HL 10 (8.8%) 3 (10.3%) 1 (1.8%) 14 (7.1%)
HH 9 (7.9%) 5 (17.2%) 12 (22.2%) 26 (13.2%)
(Continued)
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Table 2. (Continued)
LC3B dots Treatment Total
Primary Resected nCTX
Response Nonresponse
Total 114 29 54 197
Treatment Naïve vs. Chemotherapy: p-value < 0.001
Response vs Nonresponse: p-value = 0.034
https://doi.org/10.1371/journal.pone.0197610.t002
Table 3. Comparison of expression of autophagy markers LC3B and p62 in a primary resected EAC cohort and a
subcohort of neo-adjuvant chemotherapy (nCTX) treated EAC cases with paclitaxel containing regimens. Signifi-
cance was set to 0.05. Statistically significant p-values are shown in bold.
LC3B dots Treatment Total
Primary Resected nCTX
Low 95 (83.3%) 19 (67.9%) 114 (80.3%)
High 19 (16.7%) 9 (32.1%) 28 (19.7%)
Total 114 28 142
p-value = 0.108
p62 dots Treatment Total
Primary Resected nCTX
Low 95 (83.3%) 9 (32.1%) 104 (73.2%)
High 19 (16.7%) 19 (67.9%) 38 (26.8%)
Total 114 28 142
p-value < 0.001
p62 cytoplasmic Treatment Total
Primary Resected nCTX
Low 86 (75.4%) 12 (42.9%) 98 (69.0%)
High 28 (24.6%) 16 (57.1%) 44 (31.0%)
Total 114 28 142
p-value < 0.001
p62 nuclear Treatment Total
Primary Resected nCTX
Low 58 (50.9%) 16 (57.1%) 74 (52.1%)
High 56 (49.1%) 12 (42.9%) 68 (47.9%)
Total 114 28 142
p-value = 0.674
p62 dots-cyto Treatment Total
Primary Resected nCTX
Low 76 (66.7%) 4 (14.3%) 80 (56.3%)
High 38 (33.3%) 24 (85.7%) 62 (43.7%)
Total 114 28 142
p-value < 0.001
LCB/p62 Treatment Total
Primary Resected nCTX
LL 66 (57.9%) 3 (10.7%) 69 (48.6%)
LH 29 (25.4%) 16 (57.1%) 45 (31.7%)
HL 10 (8.8%) 1 (3.6%) 11 (7.7%)
HH 9 (7.9%) 8 (28.6%) 17 (12.0%)
Total 114 28 142
p-value < 0.001
https://doi.org/10.1371/journal.pone.0197610.t003
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Fig 4. Cytoplasmic expression of p62 results in decreased responsiveness of EAC cells to paclitaxel. (a) OE19 p62 knockdown cells were
transiently transfected with either a cytoplasmic or nuclear GFP-tagged p62 expression plasmid. GFP (GFP-p62 fusion proteins) and
nuclear DAPI staining as analyzed by confocal microscopy are shown. (b) Annexin V/DAPI fluorescence-activated cell sorting (FACS)
analysis of OE19 cells expressing cytoplasmic or nuclear p62 after 48 h of paclitaxel treatment. Bars represent four experimental replicates.
https://doi.org/10.1371/journal.pone.0197610.g004
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A higher number of tumor infiltrating lymphocytes correlates with
nonresponse, but does not correlate with autophagy markers in EAC ex
vivo
Host immune response assessed by TIL counts did not correlated with the expression of either
LC3B or p62 in the entire neo-adjuvant chemotherapy treated EAC cohort. It is also of note
that the cell counts for CD3+ TILs in the tumor center was significantly higher in non-
responders than responders (p = 0.041, data not shown). The same trend was seen for CD8
+ TILs (p = 0.071, data not shown).
No correlation between p62 expression levels and NRF2/KEAP1 or NF-κB
In order to further investigate the role of p62 for chemotherapy response, we additionally com-
pared the expression of some downstream proteins (NRF2/KEAP1) and NF-κB in both pri-
mary resected and neoadjuvantly treated carcinomas. In both series, we could not observed a
significant correlation between the expression of (nuclear) NRF2 and (cytoplasmic) KEAP1 or
NF-κB with p62 expression in any of the cellular compartiments (dot-like, cytoplasmic or
nuclear, data not shown).
Tumor tissue obtained from biopsies is not suitable for response prediction
or comparison with post-therapeutic samples
Assessment of pretherapeutic biopsies (n = 127) showed low pretherapeutic LC3B expression
in 62 cases and 65 cases high LC3B expression. p62 dot-like staining pattern was low in 57
cases and high in 67 cases; p62 cytoplasmic staining was low in 63 cases and high in 62 cases.
Nuclear positivity was observed only in 3 cases, and negativity in 122 cases (S4 Table). A posi-
tive correlation was seen for pre-and post-therapeutic LC3B expression (p = 0.26), but not for
p62 dot-like, cytoplasmic or nuclear expression. There was no association between LC3B and
p62 expression in the pretherapeutic biopsy tissue and histopathologic tumor response, nor
survival. In order to assure reliable staining results obtained from the superficial small biopsies,
we compared the staining patterns of the biopsies with those of non-treated, locally advanced
EAC tissue from our previous study. The expression profiles seen in the biopsies did not
match with the expected distribution across the various staining intensities, in particular with
regards to the low number of nuclear positivity for p62 and the number of cases with strong
cytoplasmic and dot like staining for LC3B. This discrepancy may be due to confounding fac-
tors, which may be related to local conditions such as necrosis, inflammation or ischemia or
due to technical reasons such as different fixation conditions of small biopsies. Therefore, we
cannot consider biopsy tissue suitable for a reliable response prediction or the comparison
between pre- and post-therapeutic expression of these proteins.
Low LC3B dot-like staining, high p62 dot-like staining and low p62 nuclear
staining is associated with a worse overall survival in the neo-adjuvant
treated EAC cohort
The following patho-morphologic parameters were of prognostic relevance in univariate anal-
ysis in the entire neo-adjuvant treated EAC cohort of 149 cases: ypT category (p = 0.040), pres-
ence of lymph node metastases (p<0.001), presence of distant metastases (p = 0.003), tumor
differentiation (grading; p = 0.054), resection status (p<0.001) and tumor regression grade
(p = 0.061; stratification into responders and non-responders p = 0.008). These parameters
were also prognostic relevant in the subcohort included in the TMA analysis (n = 83): ypT cat-
egory (p = 0.023), presence of lymph node metastases (p = 0.037), presence of distant
LC3B and p62 and chemotherapy response in esophageal adenocarcinomas
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metastases (p = 0.002), tumor differentiation (grading; p = 0.086), resection status (p = 0.015)
and tumor regression grade (p = 0.015; stratification into responders and non-responders
p = 0.005).
Low LC3B dot-like staining and combined high p62 dot-like and cytoplasmic staining or
low p62 nuclear staining was associated only in trend with a worse overall survival in the neo-
adjuvant treated EAC cohort respectively (Fig 5, data not shown for p62 nuclear staining). It is
of note that the trends observed in the univariate analysis correspond to the staining patterns
that statistically correlated to nonresponse to neo-adjuvant chemotherapy. Similarly, in a uni-
variate analysis of LC3B dot-like/p62 dot-like-cytoplasmic combination groupings showed
that the LH category showed a trend of association with an unfavorable outcome when com-
pared to other individual groups or the remaining groups collapsed into one category
Fig 5. Kaplan-Meier survival curves for autophagy markers in post-treatment tumor tissue of a neo-adjuvant EAC cohort. (A) LC3B dot-like staining
patterns, (B) p62 dot-like staining patterns (C) groupings of LC3B dot-like/p62 dot-like-cytoplasmic expression: Low LC3B/low p62 (LL), low LC3B/high p62
(LH), high LC3B/low p62 (HL) and high LC3B/high p62 (HH); and (D) LC3B dot-like/p62 dot-like-cytoplasmic expression LH versus remainder of all other
cases. For each curve the p-value is displayed on the bottom right-hand corner.
https://doi.org/10.1371/journal.pone.0197610.g005
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(p = 0.151; Fig 5), and was significantly associated with histopathological nonresponse. More-
over, low counts of CD8+ TILs, but not CD3+ were also correlated with worse overall survival
(trend; p = 0.159; p = 0.65 for CD3) in univariate analysis.
A combination of LC3B and p62 expression patterns is not a prognostic
factor in a neo-adjuvant treated EAC cohort
In a multivariate analysis encompassing all factors, that showed significant associations with
survival in univariate analysis, and the characterization of the neo-adjuvant EAC cohort into
LH versus all other groups, the most relevant factors were presence of distant metastases
p = 0.056), ypT-category (p = 0.079) and histopathological response (p = 0.119), followed by
LC3B/p62 LH status (p = 0.125). Of note, in this model, no statistically significant independent
prognostic factor was identified (Table 4).
Discussion
In the present study we investigated the role of autophagy in neo-adjuvant treatment response
in EAC, with a particular focus on paclitaxel, in vitro and ex vivo. We observed differential
responsiveness to paclitaxel treatment in a panel of four EAC cell lines. However, we found no
evidence that the observed differential response to paclitaxel in vitro is associated with differ-
ential autophagy regulation. Accumulation of the LC3B-II upon paclitaxel in the presence of
late-stage autophagy inhibitor BafA when compared to paclitaxel alone, which is indicative of
autophagy induction, was not observed. When comparing the levels of the autophagy markers
in the treatment naïve versus the neo-adjuvant treated cohort significantly higher levels of p62
dot-like and cytoplasmic, on their own and in combination, were observed in the neo-adjuvant
retreated cases. Assessing the autophagy markers LC3B and p62 in a treatment naïve EAC and
neo-adjuvant treated EAC cohort, high p62 cytoplasmic on its own or in combination with
p62 dot-like expression correlated with nonresponse. Additionally, the combination of low
LC3B dot-like/high p62 dot-like-cytoplasmic expression correlated with nonresponse.
O’Donovan et al. reported that cytoprotective autophagy was induced in an EAC cell line
resistant to 5FU and cisplatinum [23]. This can be interpreted as being in contrast to our
observations as differential response to paclitaxel treatment in EAC cell lines did not correlate
to differential autophagy regulation. However, Maskey et al. reported that while etoposide and
cisplatinum, DNA damaging agents, induced autophagy in the Jurkat T lymphocyte cell line,
paclitaxel and nocodazole, drugs which exact their anti-neoplastic via acting on microtubules,
did not induce autophagy [24]. Despite the differing cell systems, this would be in line with
our current data and would suggest that the induction of autophagy, whether cytoprotective or
not, seems to be dependent on the mode of action of the cytotoxic drug. It is of note to men-
tion that autophagy as a survival and resistance mechanism against paclitaxel treatment has
been described in many other tumor entities, highlighting the fact that the role of autophagy in
chemotherapeutic response is tumor type specific [25–27].
Other publications investigating the role of autophagy in EAC are scarce. A recent follow
up study demonstrated that the pharmacological autophagy inducers rapamycin and lithium
show diverging effects when combined with chemotherapeutics agents in esophageal cancer
cell lines [28]. Lower levels of the early autophagy initiator Beclin 1 was reported in dysplastic
Barrett’s esophagus and EAC, when compared to non-dysplastic Barrett’s esophagus and non-
neoplastic mucosa [29]. LC3B ring-like and LC3B stone-like structures were reported in
another neoadjuvant treated EAC cohort which had prognostic significance [30]. In contrast
to this study, but in line with our previous work, and most probably due to different antibodies
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used in these studies we did not observe any ring-like or stone-like LC3B staining patterns in
our neoadjuvant treated EAC cohort.
Previously we published that low p62 expression correlates with a more aggressive pheno-
type, worse prognosis and worse overall survival in the treatment naïve primary resected EAC
cohort also featured in this study [18]. It is therefore of particular interest that high p62 in the
cytoplasmic compartment on its own or in combination with low LC3B dot-like expression
correlates with nonresponse and is significantly higher in the neo-adjuvant chemotherapy
treated cohort compared to the treatment naïve cohort. Importantly, our cell line experiments
support these clinical findings since cytoplasmic expression of p62 in an EAC cell line resulted
in decreased paclitaxel sensitivity compared to EAC cells expressing nuclear p62. As low
LC3B/High p62 dot-like-cytoplasmic expression can be indicative of basal autophagy impaired
at late stages, it can be interpreted that in nonresponding tumors basal autophagy is blocked
upon neo-adjuvant chemotherapy. Given that autophagy has also been described to contribute
to apoptosis it can be hypothesized that basal autophagy competence is a prerequisite for ther-
apy induced apoptotic cell death, hence impairment correlating to nonresponse. The non-
autophagic functions of p62 could also be contributing factors to our clinical observations.
p62 is a key player in NRF2-KEAP1-antioxidant response element (ARE) pathway and p62
upregulation in this context has been described as contributing to oncogenesis [31,32]. As
increased NRF2 signaling can potentially result in an increase of the expression of pro-survival
ARE genes, and a reduction of reactive oxygen species (ROS). This would also be a mechanistic
explanation for high p62 expression correlating to nonresponse as p62 facilitates the autophagy
degradation of KEAP1, the negative regulator of NRF2. p62 can also act as pro-inflammatory
player in the NF-κB pathway. Pro-inflammatory conditions are also considered to be tumorige-
netic and could contribute to nonresponse as opposed to therapy induced cell death. We addi-
tionally investigated the association between LC3B and p62 in the post-treatment tumor tissues
and found no significant correlations. Moreover, we did not find any significant correlation
between p62 expression in any of the cellular compartments and expression levels of KEAP1,
NRF2 and NF-κB. We therefore could not establish a potential mechanistic link between the
clinical observations of p62 levels and its functions in these pathways. The observation that the
number of cases with high nuclear p62 in the primary resected cohort superseded that of the
number of cases in the neo-adjuvant chemotherapy treated cohort could potentially speak to
nuclear p62’s role as a mediator of an alternative nuclear proteolytic degradation pathway[8].
Table 4. No statistically significant independent prognostic factor was identified in a neo-adjuvant chemotherapy treated EAC cohort. HR–Hazard Ratio.
parameter HR 95% confidence interval p-value
min max
ypT category 1.722 0.939 3.157 0.079
Lymph node metastases
absent vs present
0.964 0.604 1.538 0.876
distant metastases
absent vs present
2.362 0.977 5.706 0.056
Grading
G1-G2 vs G3
1.288 0.510 3.252 0.592
Resection Status (R)
R0 vs R1
0.944 0.385 2.316 0.901
Histopathological Response
TRG1-2 vs TRG3
2.004 0.836 4.801 0.119
LC3B/p62
LH vs LL/HL/HH
0.485 0.193 1.221 0.125
https://doi.org/10.1371/journal.pone.0197610.t004
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In addition to LC3B, p62 is ubiquitously used as a marker of autophagic flux in cancer
research. However few studies focus on the mechanistic role of p62, nor the predicative and
prognostic power of p62. Some studies show that high expression of p62 in gastrointenstinal
cancers in a treatment naïve setting is associated with a more aggressive or advanced pheno-
type as well as with a worse overall survival [33,34]. This can be seen as in contrast to previous
work done in a treatment naïve setting, where low p62 was associated with a worse prognosis
[18]. Few studies focusing on p62 in a neo-adjuvant chemotherapeutic setting in gastrointesti-
nal and other cancers have been published. Park et al. found that p62 was overexpressed in the
majority of tumors in their neo-adjuvant 5FU chemotherapy treated colon carcinoma cohort.
However p62 expression did not correlate to any clinic-pathological features nor was it prog-
nostic in univariate and multivariate analysis [35]. The study by Huang et al. demonstrated
that autophagy induction, specifically accompanied by down regulation of p62, contributed to
decreased chemotherapy induced death in colon cancer cell lines [36]. However, this study
was done in the presence of therapeutic inhibition of mechanistic target of rapamycin
(mTOR), the chief negative regular of autophagy, thus in a different context as our current
study. Yu and colleagues reported that upregulation of p62 contributed to cisplatinum resis-
tance in ovarian cancer in vitro via clearance of ubiquitinated proteins [37]. If we consider p62
staining in the cytoplasmic compartment alone, this would be in line with our current findings
that higher levels of p62 correlate with nonresponse. However if we consider the groupings
with LC3B, this would be rather in contrast as the group indicative of basal autophagy
impaired at late stages correlated with nonresponse as well.
The recent genomic characterization of esophageal cancer by The Cancer Genome Atlas
(TCGA) Research Network revealed EAC is most genetically similar to the chromosomally
instable (CIN) subtype of gastric carcinoma (GC) [38]. Therefore we also looked to the body
of work done in GC with respect to the role of autophagy and chemotherapeutic response.
Most of the recent publications, using in vitro cell line based and in vivo mouse based models,
are in line with the work in EAC reporting autophagy as a survival and resistance mechanism
to DNA damaging agents [39]. For example, the upregulation of ATG5 was reported to be
associated with chemoresistance [40]. Moreover, multiple publications demonstrate that
inhibiting autophagy potentiates the cytotoxic effects of DNA damaging chemotherapeutic
drugs [41–44]. Interestingly, Yang and colleagues observed contradictory phenomena as they
published that 5FU possibly suppresses a microRNA which negatively regulates autophagy via
Beclin1, which results in increased autophagic flux and autophagic cell death [45]. Studies
investigating autophagy in GC patient tissue in a neo-adjuvant chemotherapeutic setting are
sparse [39]. It is also of importance to mention that the aforementioned studies all preceded
the TCGA publication and molecular subtyping of GC was not taken into consideration in
most cases, making correlations and comparisons with EAC studies difficult.
The fact that we had to exclude the biopsies as a viable option to assess autophagy markers
before therapy is a limitation of this study. The comparison of matched pre- and post-thera-
peutic samples would have been most informative; however, we did perform a comparative
analysis with a different treatment naïve primary resected cohort. The subset of cases treated
with 5-FU/platinum + paclitaxel regimens is rather small in number, however the results of all
our sub-analyses was all in line with those performed with the entire neo-adjuvant treated col-
lective. This suggests that this is not a paclitaxel related phenomena but a general trend regard-
less of composition of chemotherapy regimens. Using IHC in patient tissue to assess such a
dynamic process as autophagy can also be considered as a limitation as this only represents a
snapshot in the disease state. However, our strategy of using combination of both LC3B and
p62 to create an autophagic index is a more biologically informative strategy.
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In summary, we describe in this study that higher p62 expression correlates with nonresponse
to neo-adjuvant chemotherapy in EAC. Furthermore, our observation that an autophagic profile
which can be interpreted as a basal autophagy impaired at late stages also corresponds to nonre-
sponse is a novel finding. As with previously published data in a treatment naïve setting [18], the
autophagy independent roles of p62 in chemotherapeutic response cannot be ignored and war-
rants further investigation. There is also a good basis of evidence which points to the fact that the
mode of action of cytotoxic drugs may be important in autophagic regulation, which should be
taken into consideration with respect to future therapeutic strategies involving modulation of
autophagy in combination with conventional chemotherapy. We observed no differential autop-
hagy regulation upon differing responses to paclitaxel in EAC in vitro. Moreover, results of the
sub-analysis done on the subset of EAC cases receiving 5-FU/platinum + paclitaxel regimens
were in line with the results from the entire neo-adjuvant chemotherapy. Therefore in our cohort
differential expression patterns correlating to response may be a phenomenon related to DNA
damaging agents (5-FU/platinum) and not paclitaxel. The underlying mechanisms of our cur-
rent observations requires elucidation to advance future autophagy or p62 targeted therapy
modulation.
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